Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib. Case Rep Hematol 2016;2016:2389038 PMID: 27843657 PMCID: PMC5097796

Pubmed ID

27843657

Abstract

Ruxolitinib is widely in use for treatment of myeloproliferative disorders. It causes inhibition of the Janus kinase (JAK) signal transducer and activation of transcription (STAT) pathway, which plays a key role in the underlying pathophysiology of myeloproliferative diseases. We describe a case of reactivation pulmonary tuberculosis in a retired physician while on treatment with ruxolitinib. We also review the literature on opportunistic infections following use of ruxolitinib. Our case highlights the importance of screening for latent tuberculosis in patients from highly endemic areas prior to start of therapy with ruxolitinib.

Author List

Abidi MZ, Haque J, Varma P, Olteanu H, Guru Murthy GS, Dhakal B, Hari P

Authors

Binod Dhakal MD Assistant Professor in the Medicine department at Medical College of Wisconsin
Javeria Haque MD Assistant Professor in the Medicine department at Medical College of Wisconsin
Parameswaran Hari MD Chief, Professor in the Medicine department at Medical College of Wisconsin




jenkins-FCD Prod-321 98992d628744e349846c2f62ac68f241d7e1ea70